ProfileGDS5678 / 1447262_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 21% 19% 19% 19% 18% 19% 18% 19% 19% 19% 19% 19% 19% 19% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5216321
GSM967853U87-EV human glioblastoma xenograft - Control 22.4535919
GSM967854U87-EV human glioblastoma xenograft - Control 32.4626419
GSM967855U87-EV human glioblastoma xenograft - Control 42.4147319
GSM967856U87-EV human glioblastoma xenograft - Control 52.3792118
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.5163419
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.4758418
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.4437919
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.4335919
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.4537419
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.4514619
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4382619
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.4615619
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.4508319